Retatrutide, also written by its development code LY3437943, is an investigational peptide that acts at three receptors at once: GIP, GLP-1 and glucagon. The word investigational matters for this article. Retatrutide has not been approved by the FDA or the EMA, which means there is no prescribing information to quote and no regulator-reviewed pharmacokinetic table to copy. Every number attached to it comes from published clinical trial reports, and the figure most often repeated is a half-life of about six days. This page explains where that figure comes from, what the decay arithmetic built on it looks like, and how it sits next to the two approved incretin peptides that do have labels.
Where the six day figure comes from
The first-in-human pharmacokinetic work on retatrutide was published by Urva and colleagues in The Lancet in 2022, reporting a phase 1 programme in healthy participants and in people with type 2 diabetes. That report described a mean half-life of approximately six days after subcutaneous administration, a duration the authors noted was compatible with once weekly administration in later trials. The larger phase 2 obesity trial published by Jastreboff and colleagues in the New England Journal of Medicine in 2023 used that weekly interval, but the half-life figure itself still traces back to the phase 1 pharmacokinetic analysis.
A trial report and a product label are not the same kind of document, and the difference is worth stating plainly. A label consolidates pharmacokinetic parameters that a regulator has reviewed across the full submitted dataset, usually with a single headline number per parameter. A phase 1 report gives cohort means, sometimes ranges or confidence intervals, measured in a specific population under specific conditions. So when a source says retatrutide has a six day half-life, the honest version of that sentence is: a published phase 1 analysis reported a mean terminal half-life of roughly six days in the participants studied. That is a solid anchor, not a legal specification.
One practical note on sourcing. Pharmacokinetic figures circulate online attached to database identifiers that are frequently wrong, because identifiers are easy to mistype and easy to invent. The safer habit is to cite a study by author, journal and year, as above, or to cite the FDA prescribing information for compounds that have one, and then to verify the figure in the document itself before relying on it.
What a six day half-life actually means
Half-life is the time needed for a quantity to fall to half its previous value. The key property is that the process is exponential, not linear: each half-life removes half of whatever is left, so the absolute amount cleared per day shrinks as the curve flattens. Using six days as the input, the arithmetic is fixed and compound independent.
| Half-lives elapsed | Days (at 6 days per half-life) | Fraction remaining |
|---|---|---|
| 1 | 6 | 50% |
| 2 | 12 | 25% |
| 3 | 18 | 12.5% |
| 4 | 24 | 6.25% |
| 5 | 30 | about 3.1% |
| 6 | 36 | about 1.6% |
| 7 | 42 | about 0.8% |
You can run the same curve for any stated half-life, and for fractional intervals, with the peptide half-life decay calculator, which models exponential decay from a half-life you supply. Reference half-lives for a range of research peptides are collected in the peptide half-life chart, and if the concept itself is new, how to read a peptide half-life covers the vocabulary before the numbers.
Washout and steady state arithmetic
Two questions follow from any half-life figure. First, how long until a compound is effectively gone. Pharmacology convention treats four to five half-lives as practical washout, because about 94% to 97% has been eliminated by then. At six days per half-life that is 24 to 30 days, so roughly four weeks of calendar time rather than a few days. Seven half-lives, about 42 days, leaves under 1%.
Second, how long until repeated administration stops accumulating. When a compound is given at a fixed interval, each new amount lands on top of the residue from previous ones until input and clearance balance. That plateau is steady state, and it is reached after the same four to five half-lives, which again means about 24 to 30 days with a six day half-life. In the published trials retatrutide was given once weekly, so it is straightforward to put numbers on the overlap.
Seven days is 7 divided by 6, or 1.167 half-lives. The fraction surviving one weekly interval is therefore 0.5 raised to the power 1.167, which is about 0.445. In other words a little under half of each weekly amount is still present when the next one arrives. The resulting accumulation factor is 1 divided by (1 minus 0.445), about 1.8. Plasma concentrations at steady state end up roughly 1.8 times what a single administration alone would produce, and they take four to five weeks to get there. None of this is a recommendation about intervals or amounts; it is just the arithmetic of a 6 day half-life sampled every 7 days.
Compare that with a compound whose half-life is much shorter than its interval. At a 1 day half-life, seven days is seven half-liveds of decay, under 1% survives, and the accumulation factor is essentially 1.0: no meaningful overlap. The ratio between half-life and interval, not the half-life alone, is what determines accumulation.
Retatrutide next to semaglutide and tirzepatide
The three compounds are often compared, and the comparison is legitimate as long as the document class is kept visible. Two of them are approved and have FDA prescribing information. One does not.
| Compound | Reported half-life | Source document | Status |
|---|---|---|---|
| Retatrutide (LY3437943) | About 6 days | Phase 1 pharmacokinetic report, Urva et al., The Lancet, 2022 | Investigational, no approval, no label |
| Semaglutide | About 1 week (roughly 165 hours, subcutaneous) | FDA prescribing information for the subcutaneous products | Approved |
| Tirzepatide | About 5 days | FDA prescribing information | Approved |
All three land in the same multi-day band, and the structural reason is similar: each is a peptide carrying a fatty acid chain that binds reversibly to serum albumin. Albumin binding slows renal filtration and enzymatic degradation, stretching a half-life that would otherwise be measured in minutes or hours into days. Retatrutide's roughly six days sits between tirzepatide's five and semaglutide's seven, which is a narrow spread given how different the receptor profiles are.
Two cautions on reading that table. The numbers describe different parameters only loosely harmonised: terminal half-life after subcutaneous administration, usually at or near steady state, estimated in different populations with different assays. Treat the comparison as a ranking of orders of magnitude, not as a precise difference of hours. And the retatrutide row will change if the compound is ever approved, because a label number is derived from a larger dataset than a phase 1 cohort. For the labelled compounds, the detail is in semaglutide half-life and tirzepatide half-life.
What moves the number
A single published mean hides real variation. Several factors shift an individual pharmacokinetic curve away from the headline figure.
- Inter-individual variability. Phase 1 reports describe cohort means. Individual half-lives scatter around that mean, sometimes substantially.
- Body size and composition. Volume of distribution scales with body size, which changes both concentrations and the time course of elimination.
- Absorption rate. For a subcutaneous depot, absorption can be slower than elimination, so the apparent terminal half-life partly reflects how quickly the compound leaves the injection site rather than how quickly the body clears it. Pharmacologists call this flip-flop kinetics.
- Assay sensitivity and sampling window. A terminal half-life is fitted to the tail of a concentration curve. Sample for a shorter period, or with a less sensitive assay, and the fitted half-life tends to come out shorter.
- Organ function. Renal and hepatic function influence clearance for many peptides, which is why labels for approved compounds carry dedicated population subsections.
What affects peptide half-life works through these mechanisms in more general terms, and how to read a decay curve covers the shape of the plot itself.
Measurement, not a protocol
Half-life answers a timing question and nothing else. It tells you how fast a concentration falls, how long washout takes, and whether repeated administration overlaps. It says nothing about how much of anything anyone should use, and this site does not answer that question. If you arrived looking for the separate arithmetic of mg in a vial and mL of sterile diluent, that is a pure measurement conversion handled by the retatrutide vial calculator.
It is also worth keeping the stability question distinct from the pharmacokinetic one. The six day figure describes clearance from plasma in a clinical trial. How long a dissolved peptide stays intact in a vial in a refrigerator is a chemistry question governed by the material's certificate of analysis and stability data, and the two numbers are unrelated. For general handling information, not medical advice, see peptide storage and stability.
Education only. This article covers measurement, pharmacokinetics and handling for research peptides. It is not medical advice, it is not a protocol, and it does not recommend that anyone take or administer any compound. Retatrutide is an investigational compound that has not been approved by any regulator. Figures cited here are attributed to named published studies or to FDA prescribing information and should be verified in the source document.